Trial Watch: Dendritic cell-based interventions for cancer therapy Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Cell Transformation, Neoplastic
  • Molecular Targeted Therapy
  • Neoplasms

abstract

  • Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological tolerance, mature DCs are capable of priming robust, and hence therapeutically relevant, adaptive immune responses. In line with this notion, functional defects in the DC compartment have been shown to etiologically contribute to pathological conditions including (but perhaps not limited to) infectious diseases, allergic and autoimmune disorders, graft rejection and cancer. Thus, the possibility of harnessing the elevated immunological potential of DCs for anticancer therapy has attracted considerable interest from both researchers and clinicians over the last decade. Alongside, several methods have been developed not only to isolate DCs from cancer patients, expand them, load them with tumor-associated antigens and hence generate highly immunogenic clinical grade infusion products, but also to directly target DCs in vivo. This intense experimental effort has culminated in 2010 with the approval by the US FDA of a DC-based preparation (sipuleucel-T, Provenge(®)) for the treatment of asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer. As an update to the latest Trial Watch dealing with this exciting field of research (October 2012), here we summarize recent advances in DC-based anticancer regimens, covering both high-impact studies that have been published during the last 13 mo and clinical trials that have been launched in the same period to assess the antineoplastic potential of this variant of cellular immunotherapy.

publication date

  • December 18, 2013

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC3841205

Digital Object Identifier (DOI)

  • 10.4161/onci.25771

PubMed ID

  • 24286020

Additional Document Info

start page

  • e25771

volume

  • 2

number

  • 10